Document:

Exhibit 10.27.2

 

AMENDMENT
TO MANAGEMENT AGREEMENT

 

This AMENDMENT TO MANAGEMENT
AGREEMENT (this “Amendment to Management Agreement”) is made as of December 6,
2006, by and between CERBERUS-PLASMA
HOLDINGS LLC, a Delaware limited liability company (“Cerberus”), AMPERSAND
2001 LIMITED PARTNERSHIP, a Delaware limited partnership (“Ampersand”
and together with Cerberus, the “Managers”), TALECRIS BIOTHERAPEUTICS
HOLDINGS CORP., a Delaware corporation (“Holdco”) and TALECRIS
BIOTHERAPEUTICS, INC., a Delaware corporation (“Newco” and together
with Holdco, the “Companies”).

 

WHEREAS, the Companies
and the Managers have previously entered into the Management Agreement dated as
of March 31, 2005, by and between Cerberus, Ampersand, Holdco and Newco
(the “Management Agreement”).

 

WHEREAS, the parties to
the Management Agreement desire to amend the Management Agreement to provide
for the payment of certain additional fees by the Companies to the Managers in
connection with occurrence of an initial public offering;

 

NOW, THEREFORE, in
consideration of the premises and the mutual covenants contained in the
Management Agreement, and herein, the parties do hereby agree to amend the
Management Agreement as follows:

 

(A)                              Section 1
of the Management Agreement is hereby amended by deleting said Section 1
in its entirety and replacing it with the following:

 

1.                                       Term.
This Agreement shall remain in effect until
the earliest to occur of the following: (i) the Companies and the Managers
terminate this Agreement by mutual written agreement, (ii) Cerberus,
through one or more of its affiliates, ceases to control directly or
indirectly, in the aggregate, more than 30% of the voting equity interests of
Holdco, (iii) the sale, assignment, conveyance, transfer, lease or other
disposition of all or substantially all of the assets of Holdco and its
subsidiaries, taken as a whole, or Newco and its subsidiaries, taken as a
whole, whether in one transaction or a series of related transactions or (iv) the
consummation of an underwritten initial public offering of equity interests in
Holdco pursuant to an effective registration statement.

 

(B)                                Section 4
of the Management Agreement is hereby amended by adding subsection (e) as
set forth below at the end of said Section 4:

 

(e) Upon the
occurrence of an initial public offering of equity interests in Holdco and
simultaneously with the termination of this Agreement pursuant to the terms of Section 1,
the Companies, jointly and severally, shall pay a fee (the “IPO Fee”) to
the Managers (which IPO fee shall be divided between Cerberus and Ampersand in
accordance with Section 4(d)). Such IPO Fee shall be the sum of (a) five
times the Fee payable in respect of the four most recently completed fiscal
quarters of Holdco, plus (b) all reasonable out-of-pocket costs and
expenses incurred in connection with any such underwritten initial public
offering of equity interests in Holdco.

 

 

(C)                                Governing Law. ALL
QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY AND INTERPRETATION OF THIS
AMENDMENT TO MANAGEMENT AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE DOMESTIC LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING
EFFECT TO ANY CHOICE OF LAW OR CONFLICT OF LAW PROVISION OR RULE (WHETHER
OF THE STATE OF NEW YORK OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE
APPLICATION OF THE LAWS OF ANY JURISDICTION OTHER THAN THE STATE OF NEW YORK.

 

Except as set forth in
the Amendment to Management Agreement all other agreements, terms and
conditions of the Management Agreement shall remain valid, enforceable and in full
force and effect to the same extent as before this Amendment to Management
Agreement. This Amendment to the Management Agreement shall be deemed to have
been entered into on the date first above written and at a time on such date
immediately prior to the Companies entering into (i) each of the First
Lien Term Loan Credit Agreement and the Second Lien Term Loan Credit Agreement,
each dated as of December 6, 2006 and each among the Companies, Precision
Pharma Services, Inc. and Talecris Plasma Resources, Inc., as
Borrowers, the Lenders party thereto, Morgan Stanley Senior Funding, Inc.
and Goldman Sachs Credit Partners, L.P. and (ii) the Revolving Credit
Agreement, dated as of December 6, 2006 and among the Companies, Precision
Pharma Services, Inc. and Talecris Plasma Resources, Inc. as
Borrowers, the Lenders party thereto, Morgan Stanley Senior Funding, Inc.,
Goldman Sachs Credit Partners, L.P. and Wells Fargo Foothill, Inc.

 

*  * 
*  *

 

2

 

IN WITNESS WHEREOF, the
parties hereto have executed this Amendment to Management Agreement on the date
first written above.

 

	
   

  	
  TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.

  
	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ John F.
  Gaither

  	
   

  
	
   

  	
   

  	
  Name:

  	
  John F. Gaither

  
	
   

  	
   

  	
  Title:

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  TALECRIS BIOTHERAPEUTICS, INC.

  
	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ John F.
  Gaither

  	
   

  
	
   

  	
   

  	
  Name:

  	
  John J. Gaither

  
	
   

  	
   

  	
  Title:

  	
   

  
						

 

 

	
   

  	
  CERBERUS PLASMA HOLDINGS L.L.C

  
	
   

  	
   

  
	
   

  	
  By:  CERBERUS
  PARTNERS, L.P., its Managing Member,

  
	
   

  	
   

  
	
   

  	
  By:  CERBERUS
  ASSOCIATES, L.L.C.,  its General
  Partner

  

 

	
   

  	
   

  	
  By:

  	
  /s/ Seth
  Plattus

  	
   

  
	
   

  	
   

  	
  Name:

  	
  Seth Plattus

  

 

 

	
   

  	
  AMPERSAND
  VENTURE MANAGEMENT TRUST

  
	
   

  	
   

  
	
   

  	
  By: Ampersand
  Venture Management 2003 LLC, Trustee

  
	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/ RICHARD A.
  CHARPIE

  	
   

  
	
   

  	
  Richard A. Charpie, Sole Member

  

 

3Exhibit
10.31.1

 

Execution
Copy

 

RETAINED INTELLECTUAL PROPERTY LICENSE AGREEMENT

 

 

This Retained Intellectual
Property License Agreement, dated as of March 31, 2005 (this “Agreement”), is by and between Bayer
Healthcare LLC, a limited liability company organized under the laws of the State
of Delaware (“Bayer”), and Talecris
Biotherapeutics, Inc. (f/k/a NPS BioTherapeutics, Inc.), a corporation organized under the laws of the Sate of Delaware (“Newco”).

 

WITNESSETH
THAT:

 

WHEREAS, Bayer, Talecris
Holdings, LLC (f/k/a NPS Bio Holdings, LLC), a limited
liability company organized under the laws of the State of Delaware,
Talecris Biotherapeutics Holdings Corp., a corporation organized under the laws
of the state of Delaware, and Newco have entered into that certain Amended and
Restated Joint Contribution Agreement, dated as of March 30, 2005 (the “Joint Contribution Agreement”); and

WHEREAS, pursuant to the Joint
Contribution Agreement, Bayer wishes to grant and Newco wishes to receive
certain licenses under the Retained Intellectual Property (as defined in the Joint
Contribution Agreement);

NOW, THEREFORE, in
consideration of the conditions, premises and covenants set forth herein and in
the Joint Contribution Agreement, the parties hereto agree as follows:

 

ARTICLE
1

 

DEFINITIONS

 

1.1                                 Capitalized
terms not otherwise defined herein shall have the meanings set forth in the Joint
Contribution Agreement.  As used herein,
the following terms shall have the following meanings unless the context
expressly requires otherwise:

 

“Confidential
Information” means any Retained
Intellectual Property in tangible and intangible form in existence as of the
Closing Date which are  trade secrets or
not generally known, provided that none of the following information
shall be considered Confidential Information:

 

(a)                                  Information
which, as of the Closing Date, is in the public domain as evidenced by written
publication;

 

 

(b)                                 Information
which, after the Closing Date, becomes part of the public domain by written
publication without breach of this Agreement by
Newco;

 

(c)                                  Information
which was in Newco’s possession at the Closing Date and was not acquired
directly or indirectly from Bayer;

 

(d)                                 Information
acquired by Newco after the Closing Date from a third party where Newco had no
reason to believe that such third party may have received such information,
directly or indirectly, from Bayer; and

 

(e)                                  Information
developed independently by Newco after the Closing Date.

 

“Field” means the
field of manufacturing, marketing, distribution, sale and/or research and
development of all plasma-derived products, and any other plasma-derived
therapeutic protein and substitutes and equivalents therefor, provided that the
manufacturing, marketing, distribution and/or research and development of non-plasma
derived forms of Recombinant Hemophilia Products are not within the scope of
the term.

 

ARTICLE
2

 

GRANTS

 

2.1                                 Bayer hereby
grants to Newco an irrevocable, transferable (with the right to sublicense to
Newco Affiliates that are subsidiaries), royalty-free, world-wide perpetual
license to and under the Retained Intellectual Property limited to the Field,
including but not limited to the right to (i) use in the Field, reproduce for
use in the Field and prepare derivative works for use in the Field of the
Retained Intellectual Property and (ii) develop, design, manufacture, import,
make, have made, sell, offer to sell, maintain, support and otherwise
commercially exploit products or services, all in the Field, using the Retained
Intellectual Property.

 

2.2                                 This Agreement
does not give Newco any rights in any Excluded Intellectual Property or
Retained Names and Marks.

 

2.3                                 The grant of the
license in Section 2.1 shall be exclusive, subject only to outstanding valid non-exclusive
licenses granted under the Retained Intellectual Property prior to the date
hereof and those licenses set forth in Schedule 9.1 of the Bayer
Disclosure Schedule.

 

ARTICLE
3

 

TERM

 

3.1                                 This Agreement
shall commence and become effective as of the Closing Date and shall be
perpetual.

 

2

 

ARTICLE
4

 

FORCE
MAJEURE

 

4.1                                 Neither party
shall be responsible for any failure to comply with the terms of this Agreement
where and to the extent such failure is due to causes beyond its reasonable
control.  Such causes shall include,
without limitation, fire, flood, explosion, strike, labor dispute, labor
shortages, picketing, lockout, transportation embargo or failure or delay of
transportation, inability to produce materials by reason of strikes or labor
disputes, acts of God, civil riots or insurrection, acts of government or any
agency thereof, or judicial actions. 
Upon the cessation of any cause operating to excuse performance by
either party, this Agreement shall continue in full force and effect until
otherwise terminated.

 

ARTICLE
5

 

CONFIDENTIALITY

 

5.1                                 Except as
authorized under Section 5.2, Newco shall hold confidential and shall not use
or disclose to any third party, without prior written consent of the Bayer, any
Confidential Information.

 

5.2                                 Newco may
disclose Confidential Information only to the extent such disclosure is reasonably
necessary to the conduct of the Plasma Business as may be conducted from time
to time and use Confidential Information only to the extent such use is reasonably
necessary to the conduct of the Plasma Business.  Disclosure by Newco of Confidential
Information as required by Applicable Law shall not constitute a breach of this
Agreement provided that, if not prohibited by Applicable Law, Newco provides
Bayer with prior written notice and takes reasonable steps in connection
therewith to protect such Confidential Information from unauthorized use and
disclosure.

 

ARTICLE
6

 

WARRANTY
DISCLAIMERS

 

6.1                                 Except as set
forth in the Joint Contribution Agreement, Bayer makes no representations,
extends no warranties of any kind, either express or implied, and assumes no
responsibilities whatever with respect to the Retained Intellectual Property or
the conduct of the Plasma Business.

 

6.2                                 Nothing in this
Agreement shall be construed as

 

3

 

(a)                                  a warranty or
representation by Bayer as to the validity or scope of any of the Retained
Intellectual Property; or

 

(b)                                 a warranty or
representation that anything made, used, sold, or otherwise disposed of under
any license granted in this Agreement is or will be free from infringement of
Intellectual Property of third parties; or

 

(c)                                  a requirement
that either party file any patent application, secure any patent or maintain
any patent in force or that Bayer shall maintain the secrecy of any
Confidential Information which is included in
Retained Intellectual Property; or

 

(d)                                 an obligation
to bring or prosecute actions or suits against third parties for infringement
or violation of any Retained Intellectual Property, provided that in the event
that Newco, by law, has standing to enforce rights licensed hereunder and desires
to enforce such rights:

 

(i)                                     Newco shall
provide notice to Bayer specifying all information in Newco’s possession regarding
infringement of such rights by a third party;

 

(ii)                                  Newco and Bayer
shall meet and discuss enforcement efforts reasonable to both Bayer and Newco
in light of the applicable circumstances; and

 

(iii)                               Bayer shall not
unreasonably withhold assistance in connection with such enforcement efforts,
provided that Newco shall be responsible for the reasonable direct costs and
expenses of Bayer which shall be reasonably documented, including but not
limited to direct internal costs, out-of-pocket expenses, and attorney fees for
counsel for Bayer selected at the sole discretion of Bayer; or

 

(e)                                  an obligation
to furnish any manufacturing or technical information outside of Retained
Intellectual Property; or

 

(f)                                    conferring a
right to use in advertising, publicity or otherwise any trademark or trade name
of Bayer; or

 

(g)                                 granting by
implication, estoppel, or otherwise, any licenses or rights under patents of
Bayer other than the Retained Intellectual Property, regardless of whether such
other patents are dominant of or subordinate to any patents within the Retained
Intellectual Property.

 

ARTICLE
7

 

GENERAL
PROVISIONS

 

7.1                                 Governing law.  This Agreement shall be governed by and
construed in accordance with the laws of the State of New York applicable to
contracts made and performed

 

4

 

therein, without giving
effect to the principles of conflicts of law thereof, except for matters where
the principles of conflicts of law in the United States would provide for
applicability of the federal intellectual property laws of the United States.

 

7.2                                 Assignment;
parties and interest.  This
Agreement and all of the provisions hereof shall be binding upon and inure to
the benefit of the parties hereto and thereto and their respective successors
and assigns. Neither this Agreement nor any of the rights, interests or
obligations hereunder may be assigned by any of the parties without the prior
written consent of the other party hereto, except that each party may at any
time assign any or all of its rights or obligations hereunder to one of its
wholly owned subsidiaries (but no such assignment shall relieve such party of
any obligations under this Agreement). 
Notwithstanding the foregoing, and without limiting anything to the
contrary in Section 2.1, Newco may assign this Agreement and any or all rights
or obligations hereunder to (i) any affiliate of Newco provided that any such
affiliate becomes a party to this Agreement, (ii) any lender of Newco as
collateral security or (iii) any successor in interest to Newco; provided that
any such successor becomes a party to this Agreement; provided that no
assignment under (i), (ii) or (iii) above shall relieve Newco from any
obligation hereunder.  Bayer may assign
this Agreement and any or all rights or obligations hereunder to (i) any
affiliate of Bayer, provided that any such affiliate becomes a party to this
Agreement or (ii) any successor in interest to Bayer, provided that any such
successor becomes a party to this Agreement; provided that no assignment under
(i) or (ii) above shall relieve Bayer from any obligation hereunder.  Any purported assignment in contravention of
this Section 7.2 shall be void.  Notwithstanding
the foregoing, nothing in this Agreement shall impact Bayer’s rights of
alienation of any of the Retained Intellectual Property or otherwise restrict
any type of transfer or license thereto not inconsistent herewith.  This Agreement is not intended to confer upon
any other person any rights or remedies hereunder.

 

7.3                                 Counterparts.  This Agreement may be executed in one or more
counterparts, each of which shall be deemed to be an original and all of which
together shall be deemed to be one and the same instrument.

 

7.4                                 Notices.  All notices, requests, demands, consents and
other communications required or permitted hereunder shall be in writing and
shall be delivered in the manner set forth in the Joint Contribution Agreement.

 

7.5                                 Amendments; No
Waivers.

 

(a)                                  Any provision
of this Agreement may be amended or waived if, and only if, such amendment or
waiver is in writing and signed, in the case of an amendment, by Bayer and Newco,
or in the case of a waiver, by the party against whom the waiver is to be
effective.

 

(b)                                 No failure or
delay by either party in exercising any right, power or privilege hereunder
shall operate as a waiver thereof nor shall any single or partial exercise
thereof preclude any other or further exercise thereof or the exercise of any
other right, power or privilege.  The
rights and remedies herein provided shall be cumulative and not exclusive of
any rights or remedies provided by Applicable Law.

 

5

 

7.6                                 Captions.  The captions herein are included for
convenience of reference only and shall be ignored in the construction or
interpretation hereof.

 

7.7.                              Rights and
Remedies.  The rights
and remedies of the parties hereunder shall be governed exclusively under the
Joint Contribution Agreement.

 

7.8.                              Conflicts.  In the event of any conflicts between the
provisions of this Agreement and the Joint Contribution Agreement, the
provisions of the Joint Contribution Agreement shall prevail and control except
with respect to Sections 7.1 and 7.2 hereof.

 

{Remainder of this page has been intentionally left blank}

 

6

 

IN WITNESS WHEREOF, the
undersigned have duly executed and delivered this Agreement as of the date
first written above.

 

	
   

  	
   

  	
  BAYER HEALTHCARE LLC

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ AUTHORIZED SIGNATORY

  
	
   

  	
   

  	
  Name:

  	
  Authorized Signatory

  
	
   

  	
   

  	
  Title:

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  BAYER HEALTHCARE LLC

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ AUTHORIZED SIGNATORY

  
	
   

  	
   

  	
  Name:

  	
  Authorized Signatory

  
	
   

  	
   

  	
  Title:

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  TALECRIS BIOTHERAPEUTICS,
  INC.

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ LAWRENCE D. STERN

  
	
   

  	
   

  	
  Name:

  	
  Lawrence D. Stern

  
	
   

  	
   

  	
  Title:

  	
  Executive Chairman

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]